Form 4: Akari Therapeutics CFO Granted Equity Awards

Akari Therapeutics' Interim CFO, Kameel D. Farag, was granted restricted stock units representing 58,619 American Depositary Shares.

Summary

• Kameel D. Farag, Interim CFO of Akari Therapeutics Plc (AKTX), reported the acquisition of 58,619 American Depositary Shares (ADSs) through restricted stock unit (RSU) grants.
• These ADSs were granted at a reported value of $0.75 per ADS.
• The grants consist of two tranches: 32,000 ADSs vesting on January 1, 2026, and 26,619 ADSs vesting on February 15, 2026.
• Each American Depositary Share (ADS) represents 2,000 Ordinary Shares of Akari Therapeutics with a par value of $0.0001 per Ordinary Share.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a key executive is generally viewed as a positive for aligning management incentives with shareholder interests, though it does not represent a direct cash investment by the insider.

Positives

• The grant of restricted stock units aligns the Interim CFO's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• Increased beneficial ownership by a key executive can signal confidence in the company's future prospects and long-term strategy.

Negatives

• Restricted stock units are a form of compensation and do not represent a direct cash investment by the executive into the company's shares.
• The future vesting of these RSUs will result in the issuance of new shares, potentially leading to minor dilution for existing shareholders.

Risks

• The value of the granted RSUs is subject to the future market price of Akari Therapeutics' American Depositary Shares, which can fluctuate based on company performance and broader market conditions.
• Vesting of the RSUs is typically contingent on continued employment and may include other performance conditions not detailed in this specific Form 4, meaning the executive may not ultimately receive all shares.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on an insider's equity transaction.

Industry Context

Equity-based compensation, such as restricted stock units, is a standard practice across various industries, particularly in biotechnology and pharmaceutical sectors, to attract, retain, and incentivize key executives by aligning their long-term interests with shareholder value creation.

Comparison to Industry Standards

• RSU grants are a common form of executive compensation, comparable to practices at other small-cap biotech firms. For instance, similar grants are observed at companies like Athersys (ATHX) or Sorrento Therapeutics (SRNEQ) for their executives, aiming to tie compensation to long-term performance.
• The specific grant size of 58,619 ADSs (representing 117,238,000 ordinary shares) for an Interim CFO would need to be benchmarked against peer companies' compensation structures, considering Akari's market capitalization and stage of development to assess its relative scale.

Related Party Transactions

• The grant of restricted stock units to the Interim CFO constitutes an executive compensation arrangement, which is a form of related party transaction common in corporate governance.

Stakeholder Impact

• Shareholders: The grant aligns the Interim CFO's long-term interests with shareholder value. However, the future vesting will lead to minor dilution from the issuance of new shares.
• Employees: This transaction is specific to a key executive's compensation and does not directly impact the broader employee base, though it reflects the company's executive incentive structure.

Next Steps

• The granted restricted stock units are scheduled to vest in two tranches on January 1, 2026, and February 15, 2026, at which point the Interim CFO will beneficially own the underlying shares.

Key Dates

Keywords

Akari Therapeutics, AKTX, Form 4, RSU, Restricted Stock Units, Executive Compensation, Equity Grant, Insider Transaction, Kameel D. Farag